Literature DB >> 23196068

L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells.

Branden J Stansley1, Bryan K Yamamoto.   

Abstract

L-dopa is a precursor for dopamine synthesis and a mainstay treatment for Parkinson's disease. However, l-dopa therapy is not without side effects that may be attributed to non-dopaminergic mechanisms. Synthesized dopamine can be neurotoxic through its enzymatic degradation by monoamine oxidase (MAO) to form the reactive byproduct, hydrogen peroxide and hydroxyl radicals or through auto-oxidation to form highly reactive quinones that can bind proteins and render them non-functional. Since l-dopa could be decarboxylated by aromatic amino acid decarboxylase (AADC) present within both dopamine and serotonin neurons, it was hypothesized that serotonin neurons convert l-dopa into dopamine to generate excessive reactive oxygen species and quinoproteins that ultimately lead to serotonin neuron death. To examine the effects of l-dopa on serotonin neurons, the RN46A-B14 cell line was used. These immortalized serotonergic cell cultures were terminally differentiated and then incubated with varying concentrations of l-dopa. Results show that RN46A-B14 cells contain AADC and can synthesize dopamine after incubation with l-dopa. Furthermore, l-dopa dose-dependently increased intracellular reactive oxygen species (ROS) and cell death. Dopamine, ROS production and cell death were attenuated by co-incubation with the AADC inhibitor, NSD-1015. The MAO inhibitor, pargyline, also attenuated cell death and ROS after l-dopa treatment. Lastly, quinoprotein formation was enhanced significantly by incubation with l-dopa. Taken together, these data illustrate that serotonergic cells can produce dopamine and that the accumulation of dopamine after l-dopa and its subsequent degradation can lead to ROS production and death of RN46A-B14 serotonergic cells.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23196068      PMCID: PMC3638241          DOI: 10.1016/j.neuropharm.2012.11.010

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  39 in total

1.  Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations.

Authors:  Dag Nyholm; Hans Lennernäs; Cecilia Gomes-Trolin; Sten-Magnus Aquilonius
Journal:  Clin Neuropharmacol       Date:  2002 Mar-Apr       Impact factor: 1.592

2.  Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine.

Authors:  R Pedrosa; P Soares-da-Silva
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 3.  Neuronal dopa decarboxylase.

Authors:  Y L Siow; K Dakshinamurti
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

4.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

Authors:  D G Graham
Journal:  Mol Pharmacol       Date:  1978-07       Impact factor: 4.436

5.  The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life.

Authors:  Angelo Antonini; Paolo Barone; Roberto Marconi; Letterio Morgante; Salvatore Zappulla; Francesco Ernesto Pontieri; Silvia Ramat; Maria Gabriella Ceravolo; Giuseppe Meco; Giulio Cicarelli; Massimo Pederzoli; Michela Manfredi; Roberto Ceravolo; Marco Mucchiut; Giampiero Volpe; Giovanni Abbruzzese; Edo Bottacchi; Luigi Bartolomei; Giuseppe Ciacci; Antonino Cannas; Maria Giovanna Randisi; Alfredo Petrone; Mario Baratti; Vincenzo Toni; Giovanni Cossu; Paolo Del Dotto; Anna Rita Bentivoglio; Michele Abrignani; Rossana Scala; Franco Pennisi; Rocco Quatrale; Rosa Maria Gaglio; Alessandra Nicoletti; Michele Perini; Tania Avarello; Antonio Pisani; Augusto Scaglioni; Paolo Emilio Martinelli; Francesco Iemolo; Laura Ferigo; Pasqualino Simone; Paola Soliveri; Biagio Troianiello; Domenico Consoli; Alessandro Mauro; Leonardo Lopiano; Giuseppe Nastasi; Carlo Colosimo
Journal:  J Neurol       Date:  2012-06-19       Impact factor: 4.849

6.  Critical role of mitochondrial reactive oxygen species formation in visible laser irradiation-induced apoptosis in rat brain astrocytes (RBA-1).

Authors:  Mei-Jie Jou; Shuo-Bin Jou; Hung-Ming Chen; Chi-Hung Lin; Tsung-I Peng
Journal:  J Biomed Sci       Date:  2002       Impact factor: 8.410

7.  Specific detection of quinoproteins by redox-cycling staining.

Authors:  M A Paz; R Flückiger; A Boak; H M Kagan; P M Gallop
Journal:  J Biol Chem       Date:  1991-01-15       Impact factor: 5.157

Review 8.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  L-Dopa-induced release of cerebral monoamines.

Authors:  K Y Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

10.  Resveratrol attenuates L-DOPA-induced hydrogen peroxide toxicity in neuronal cells.

Authors:  Carina S Peritore; Angela Ho; Bryan K Yamamoto; Scott E Schaus
Journal:  Neuroreport       Date:  2012-12-05       Impact factor: 1.837

View more
  28 in total

Review 1.  Presynaptic effects of levodopa and their possible role in dyskinesia.

Authors:  Eugene V Mosharov; Anders Borgkvist; David Sulzer
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

2.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

3.  Effects of Antidepressants on DSP4/CPT-Induced DNA Damage Response in Neuroblastoma SH-SY5Y Cells.

Authors:  Yan Wang; Benjamin A Hilton; Kui Cui; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2015-06-03       Impact factor: 3.911

Review 4.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

Review 5.  Neuroinflammation as a risk factor for attention deficit hyperactivity disorder.

Authors:  Geoffrey A Dunn; Joel T Nigg; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2019-05-16       Impact factor: 3.533

Review 6.  Catecholamine/Serotonin interactions: systems thinking for brain function and disease.

Authors:  Julie G Hensler; Francesc Artigas; Analía Bortolozzi; Lynette C Daws; Philippe De Deurwaerdère; Léa Milan; Sylvia Navailles; Wouter Koek
Journal:  Adv Pharmacol       Date:  2013

7.  Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.

Authors:  Rashed Abdullah; Ketan S Patil; Benjamin Rosen; Ramavati Pal; Shubhangi Prabhudesai; Sungsu Lee; Indranil Basak; Esthelle Hoedt; Peter Yang; Keith Panick; Hsin-Pin Ho; Emmanuel Chang; Charalampos Tzoulis; Jan Petter Larsen; Thomas A Neubert; Guido Alves; Simon G Møller
Journal:  Mol Neurobiol       Date:  2016-11-11       Impact factor: 5.590

Review 8.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

9.  Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  J Pharmacol Exp Ther       Date:  2014-09-11       Impact factor: 4.030

10.  Interrelationships Between BDNF, Superoxide Dismutase, and Cognitive Impairment in Drug-Naive First-Episode Patients With Schizophrenia.

Authors:  Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.